抗精神病药联合用药：长期临床实践相关因素的综合评估。
Antipsychotic polypharmacy: a comprehensive evaluation of relevant correlates of a long-standing clinical practice.
机构信息
The Zucker Hillside Hospital, Division of Psychiatry Research, North Shore-LIJ Health System, 75-59, 263rd Street, Glen Oaks, NY 11004, USA.
出版信息
Psychiatr Clin North Am. 2012 Sep;35(3):661-81. doi: 10.1016/j.psc.2012.06.007. Epub 2012 Jul 24.
Abstract
Antipsychotic polypharmacy (APP) is common in the treatment of schizophrenia spectrum disorders. The literature indicates that APP is related to patient, illness, and treatment variables that are proxy measures for greater illness acuity, severity, complexity, and chronicity. The largely unknown relative risks and benefits of APP need to be weighed against the known risks and benefits of clozapine for treatment-resistant patients. To inform evidence-based clinical practice, controlled, high-quality antipsychotic combination and discontinuation trials are necessary to determine the effectiveness, safety, and role of APP in the management of severely ill patients with insufficient response to antipsychotic monotherapy.
摘要
抗精神病药联用（APP）在精神分裂症谱系障碍的治疗中很常见。文献表明，APP 与患者、疾病和治疗变量有关，这些变量是疾病严重程度、复杂性和慢性程度的替代指标。APP 的相对风险和益处尚不清楚，需要与氯氮平治疗抵抗患者的已知风险和益处进行权衡。为了提供循证临床实践，需要进行对照、高质量的抗精神病药联合和停药试验，以确定 APP 在管理对抗精神病药单药治疗反应不足的重度疾病患者中的有效性、安全性和作用。
相似文献
1
Antipsychotic polypharmacy: a comprehensive evaluation of relevant correlates of a long-standing clinical practice.
Psychiatr Clin North Am. 2012 Sep;35(3):661-81. doi: 10.1016/j.psc.2012.06.007. Epub 2012 Jul 24.
2
Maintenance phase treatment of psychotic disorders in outpatients from Serbia - focus on long-term benzodiazepine use.
Int J Psychiatry Clin Pract. 2020 Sep;24(3):315-321. doi: 10.1080/13651501.2020.1767788. Epub 2020 May 27.
3
Frequency and correlates of antipsychotic polypharmacy among patients with schizophrenia in Denmark: A nation-wide pharmacoepidemiological study.
Eur Neuropsychopharmacol. 2015 Oct;25(10):1669-76. doi: 10.1016/j.euroneuro.2015.04.027. Epub 2015 May 7.
4
Combination therapy: is clinical practice leading the way?
J Clin Psychiatry. 2003 Jan;64(1):94; author reply 94-6. doi: 10.4088/jcp.v64n0117a.
5
Antipsychotic polypharmacy in schizophrenia: benefits and risks.
CNS Drugs. 2011 May;25(5):383-99. doi: 10.2165/11587810-000000000-00000.
6
Antipsychotic Polypharmacy Among Patients With Schizophrenia in Africa: A Systematic Review and Meta-Analysis.
Int J Neuropsychopharmacol. 2021 Dec 8;24(12):956-964. doi: 10.1093/ijnp/pyab046.
7
The risks and benefits of switching patients with schizophrenia or schizoaffective disorder from two to one antipsychotic medication: a randomized controlled trial.
Schizophr Res. 2015 Aug;166(1-3):194-200. doi: 10.1016/j.schres.2015.05.038. Epub 2015 Jun 30.
8
Prevalence and nature of antipsychotic polypharmacy among inpatients with schizophrenia spectrum disorders at an Australian mental health service.
Australas Psychiatry. 2014 Dec;22(6):546-50. doi: 10.1177/1039856214546672. Epub 2014 Aug 21.
9
Prevalence and correlates of antipsychotic polypharmacy in Hong Kong.
Asian J Psychiatr. 2018 Mar;33:113-120. doi: 10.1016/j.ajp.2018.03.012. Epub 2018 Mar 10.
10
Prevalence, trends, and factors associated with antipsychotic polypharmacy among Medicaid-eligible schizophrenia patients, 1998-2000.
J Clin Psychiatry. 2004 Oct;65(10):1377-88. doi: 10.4088/jcp.v65n1013.
引用本文的文献
1
Effectiveness of clozapine augmentation with specific doses of other antipsychotics in schizophrenia: a meta-analysis from two nationwide cohorts.
World Psychiatry. 2025 Jun;24(2):250-259. doi: 10.1002/wps.21316.
2
Development of a simultaneous LC-MS/MS analytical method for plasma: 16 antipsychotics approved in Japan and 4 drug metabolites.
Anal Sci. 2024 Sep;40(9):1749-1763. doi: 10.1007/s44211-024-00619-2. Epub 2024 Jun 25.
3
Nationwide study on antipsychotic polypharmacy among forensic psychiatric patients.
Int J Circumpolar Health. 2023 Dec;82(1):2218654. doi: 10.1080/22423982.2023.2218654.
4
The pathophysiology of rapid fluctuations in mental status associated with olanzapine: A case report.
Front Psychiatry. 2022 Dec 1;13:1028350. doi: 10.3389/fpsyt.2022.1028350. eCollection 2022.
5
A Survey Study on Clinicians' Rationale and Attitude Towards the Prescription of Antipsychotic Polypharmacy in the East Perth Metropolitan Area in Western Australia.
Cureus. 2023 Apr 7;15(4):e37234. doi: 10.7759/cureus.37234. eCollection 2023 Apr.
6
Case report: Successful administration of cariprazine in a young, severely ill patient with recurrent relapses of schizophrenia and persistent negative symptoms.
Front Psychiatry. 2023 Mar 9;14:1134692. doi: 10.3389/fpsyt.2023.1134692. eCollection 2023.
7
Polypharmacy Management of Antipsychotics in Patients with Schizophrenia.
Medicina (Kaunas). 2022 Nov 3;58(11):1584. doi: 10.3390/medicina58111584.
8
The dilemma of polypharmacy in psychosis: is it worth combining partial and full dopamine modulation?
Int Clin Psychopharmacol. 2022 Nov 1;37(6):263-275. doi: 10.1097/YIC.0000000000000417. Epub 2022 Jul 12.
9
Therapeutic drug monitoring in children and adolescents with schizophrenia and other psychotic disorders using risperidone.
J Neural Transm (Vienna). 2022 Jun;129(5-6):689-701. doi: 10.1007/s00702-022-02485-6. Epub 2022 Mar 18.
10
Anticholinergic Burden and Cognitive Performance in Patients With Schizophrenia: A Systematic Literature Review.
Front Psychiatry. 2021 Dec 28;12:779607. doi: 10.3389/fpsyt.2021.779607. eCollection 2021.
本文引用的文献
1
Pharmacological treatment of hospitalised schizophrenic patients in Belgium.
Int J Psychiatry Clin Pract. 2006;10(4):285-90. doi: 10.1080/13651500600811206.
2
A prescription survey of the use of atypical antipsychotics for hospital inpatients in the United Kingdom.
Int J Psychiatry Clin Pract. 2000;4(1):41-6. doi: 10.1080/13651500052048749.
3
Safety and tolerability of antipsychotic polypharmacy.
Expert Opin Drug Saf. 2012 Jul;11(4):527-42. doi: 10.1517/14740338.2012.683523. Epub 2012 May 8.
4
Prevalence and correlates of antipsychotic polypharmacy: a systematic review and meta-regression of global and regional trends from the 1970s to 2009.
Schizophr Res. 2012 Jun;138(1):18-28. doi: 10.1016/j.schres.2012.03.018. Epub 2012 Apr 24.
5
What are we looking for in new antipsychotics?
J Clin Psychiatry. 2011;72 Suppl 1:9-13. doi: 10.4088/JCP.10075su1.02.
6
Quantifying clinical relevance in the treatment of schizophrenia.
Clin Ther. 2011 Dec;33(12):B16-39. doi: 10.1016/j.clinthera.2011.11.016.
7
Impact of feedback from pharmacists in reducing antipsychotic polypharmacy in schizophrenia.
Psychiatry Clin Neurosci. 2011 Dec;65(7):676-8. doi: 10.1111/j.1440-1819.2011.02280.x.
8
Randomized controlled trials in schizophrenia: opportunities, limitations, and trial design alternatives.
Dialogues Clin Neurosci. 2011;13(2):155-72. doi: 10.31887/DCNS.2011.13.2/ccorrell.
9
Antipsychotic utilisation and polypharmacy in Italian residential facilities: a survey.
Epidemiol Psychiatr Sci. 2011 Jun;20(2):171-9. doi: 10.1017/s2045796011000242.
10
Effectiveness of switching from antipsychotic polypharmacy to monotherapy.
Am J Psychiatry. 2011 Jul;168(7):702-8. doi: 10.1176/appi.ajp.2011.10060908. Epub 2011 May 2.
Zotero 插件